Abstract
Neuroblastoma, one of the common malignant childhood tumors, arises from neuroblast cells derived from the neural crest and destined for the adrenal medulla and the sympathetic nervous system and shows remarkable biological heterogeneity, resulting in favorable or unfavorable outcomes. Some neuroblastomas tend to regress spontaneously in infants or to differentiate into a benign ganglioneuroma in older patients. In other instances, the tumors make rapid progress with a fatal outcome. This heterogeneity within neuroblastoma depends on the molecular characteristics of tumor cells. Several distinct genomic alterations have been found in neuroblastoma, including MYCN amplification, ploidy changes, deletion of the short arm of chromosome 1, gain of chromosome 17q, and deletion of 11q. The difference of expression was also found in genes related to cellular growth, differentiation, and apoptosis of neural network including Trk receptor tyrosine kinase and telomerase activity. This review discusses the extensive heterogeneity of neuroblastoma at molecular level, providing evidences that neuroblastoma is not a single disease. This should lead to more risk-adapted therapies according to the genetic markers by which individual neuroblastomas are biologically characterized.
Keywords: neuroblastoma, prognosis, mycn, ploidy, chromosome, telomerase, telomere, apoptosis
Current Genomics
Title: Molecular and Biological Heterogeneity in Neuroblastoma
Volume: 6 Issue: 5
Author(s): E. Hiyama and K. Hiyama
Affiliation:
Keywords: neuroblastoma, prognosis, mycn, ploidy, chromosome, telomerase, telomere, apoptosis
Abstract: Neuroblastoma, one of the common malignant childhood tumors, arises from neuroblast cells derived from the neural crest and destined for the adrenal medulla and the sympathetic nervous system and shows remarkable biological heterogeneity, resulting in favorable or unfavorable outcomes. Some neuroblastomas tend to regress spontaneously in infants or to differentiate into a benign ganglioneuroma in older patients. In other instances, the tumors make rapid progress with a fatal outcome. This heterogeneity within neuroblastoma depends on the molecular characteristics of tumor cells. Several distinct genomic alterations have been found in neuroblastoma, including MYCN amplification, ploidy changes, deletion of the short arm of chromosome 1, gain of chromosome 17q, and deletion of 11q. The difference of expression was also found in genes related to cellular growth, differentiation, and apoptosis of neural network including Trk receptor tyrosine kinase and telomerase activity. This review discusses the extensive heterogeneity of neuroblastoma at molecular level, providing evidences that neuroblastoma is not a single disease. This should lead to more risk-adapted therapies according to the genetic markers by which individual neuroblastomas are biologically characterized.
Export Options
About this article
Cite this article as:
Hiyama E. and Hiyama K., Molecular and Biological Heterogeneity in Neuroblastoma, Current Genomics 2005; 6 (5) . https://dx.doi.org/10.2174/1389202054750202
DOI https://dx.doi.org/10.2174/1389202054750202 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Genomic Insights into Oncology: Harnessing Machine Learning for Breakthroughs in Cancer Genomics.
This special issue aims to explore the cutting-edge intersection of genomics and oncology, with a strong emphasis on original data and experimental validation. While maintaining the focus on how machine learning and advanced data analysis techniques are revolutionizing our understanding and treatment of cancer, this issue will prioritize contributions that ...read more
Integrating Artificial Intelligence and Omics Approaches in Complex Diseases
Recent advancements in AI and omics methodologies have revolutionized the landscape of biomedical research, enabling us to extract valuable information from vast amounts of complex data. By combining AI algorithms with omics technologies such as genomics, proteomics, metabolomics, and transcriptomics, researchers can obtain a more comprehensive and multi-dimensional analysis of ...read more
Integrating Machine Learning with Genome Science: Pioneering Developments and Future Directions
Integrating machine learning (ML) with genome science is driving transformative advancements in fields such as genomics, personalized medicine, and drug discovery. Genomic data is vast and complex, making traditional analysis methods inadequate for uncovering deep insights. Machine learning, particularly deep learning models like convolutional neural networks (CNNs) and recurrent neural ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets New Preparative Approaches for Micro and Nano Drug Delivery Carriers
Current Drug Delivery Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Current Management of Neonatal Soft-tissue Sarcomas and Benign Tumors with Local Aggressiveness
Current Pediatric Reviews Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine Anti-Inflammatory and Pro-Resolving Effects of N-3 PUFA in Cancers: Structures and Mechanisms
Current Topics in Medicinal Chemistry Perspectives of Plant Natural Products in Inhibition of Cancer Invasion and Metastasis by Regulating Multiple Signaling Pathways
Current Medicinal Chemistry Sera/Organ Lysates of Selected Animals Living in Polluted Environments Exhibit Cytotoxicity against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
Current Protein & Peptide Science STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets
Current Drug Targets Targeted Regulation of PI3K/Akt/mTOR/NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Dissecting the Therapeutic Relevance of Gene Therapy in NeuroAIDS: An Evolving Epidemic
Current Gene Therapy